WHO ICTRP trial
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150…
IRCT20200105046010N46 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20200105046010N46 |
|---|---|
| Public title | In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland) |
| Scientific title | In- Vivo Bioequivalence study of Erlotinib tablet 150 mg Actero Pharma. with brand drug (TARCEVA® 150 mg, Rosche, Switzerland) in Iranian healthy volunteers. |
| Primary sponsor | Actero Pharma. Co. |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | Bio equivalence test. |
| Interventions | Intervention 1: Intervention group: One test tablet (Erlotinib tablet 150 mg produced by Actero Pharma.) will be received. Blood samples will be taken for 72 hours at the mentioned times after drug administration and the concentration of… |
| Registration date | Dec 7, 2021 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: